Psychiatric NP Scope of Practice for Anxiety in California

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for anxiety treatment, you’re probably asking: Can I legally prescribe benzodiazepines or other controlled substances remotely? What’s the difference between treating patients in California versus Texas or Florida?

The answer: Yes, you can prescribe anxiety medications via telehealth in 2025—but the rules vary dramatically by state and provider type. Federal COVID-era flexibilities remain in place through at least December 2025, allowing controlled substance prescribing without an initial in-person visit. However, each state layers on its own licensing requirements, prescribing limits (especially for NPs), and compliance obligations like prescription monitoring checks.

This isn’t about memorizing obscure regulations. It’s about understanding the regulatory landscape so you can treat anxiety patients safely, legally, and confidently across state lines. Let’s break down what actually matters for your practice.

Federal Rules: The DEA Baseline for Controlled Anxiety Medications

The Ryan Haight Act is your starting point. Under normal circumstances, federal law prohibits prescribing any controlled substance ‘by means of the Internet’ without a prior in-person medical evaluation. For anxiety providers, that meant you historically couldn’t initiate a benzodiazepine prescription (Xanax, Klonopin, Ativan—all Schedule IV controlled substances) via telehealth alone.

COVID changed everything. In March 2020, the DEA invoked public health emergency exceptions, allowing practitioners to prescribe Schedule II-V controlled substances via telemedicine without any in-person exam. These flexibilities have been extended three times, most recently through December 31, 2025.

What This Means Right Now

As of early 2026, you can:

• Evaluate a new anxiety patient entirely via telehealth (video preferred)
• Prescribe benzodiazepines, SSRIs, or other anxiety medications after that virtual assessment
• Continue treatment remotely without arranging an in-person visit

The catch: This is temporary. The DEA proposed rules in 2023 that would have reinstated in-person requirements (with limited 30-day tele-prescribing allowances), but after 38,000 public comments—mostly from mental health providers—the agency postponed those restrictions to develop ‘a new path forward for telemedicine.’ Translation: expect potential rule changes in late 2025 or 2026.

Practical Reality Check

Most anxiety medications aren’t controlled substances. SSRIs (Lexapro, Zoloft), SNRIs (Effexor), buspirone, hydroxyzine—none of these are restricted by the Ryan Haight Act. You can prescribe them via telehealth exactly as you would in person, following standard clinical guidelines.

The regulatory complexity centers on benzodiazepines (Schedule IV) and, less commonly for anxiety, stimulants (Schedule II, when treating comorbid ADHD). These are the medications that trigger DEA scrutiny and state-specific prescribing limits, especially for nurse practitioners.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists: Full Authority, State-Specific Compliance

If you’re a board-certified psychiatrist (MD or DO), your scope of practice for anxiety is unrestricted in every state. You can:

• Diagnose any anxiety disorder independently
• Provide medication management and psychotherapy
• Prescribe any anxiolytic medication, from SSRIs to benzodiazepines to off-label beta-blockers
• Make treatment decisions without supervision or collaborative agreements

No state limits what psychiatrists can prescribe for anxiety. Your medical license grants full prescriptive authority, provided you comply with federal and state prescribing regulations.

The Real Regulatory Burdens

Your compliance obligations center on three areas:

1. Multi-State LicensingYou must hold a valid medical license in every state where your patients are located. Treating a New York patient while licensed only in California is practicing medicine without a license—a serious violation.

The Interstate Medical Licensure Compact (IMLC) can help. Texas, Florida, Illinois, and Pennsylvania are member states; California and New York are not. If you’re IMLC-eligible, you can expedite licenses in member states. Otherwise, expect 3-6 months and $500-2,000 per state license.

2. Prescription Drug Monitoring Programs (PDMPs)Almost every state mandates checking the state PDMP database before prescribing controlled substances. Requirements vary:

• New York: Must check the I-STOP registry before every Schedule II-IV prescription (including benzodiazepines)
• California: Check CURES database initially and at least every 4 months for ongoing controlled prescriptions
• Pennsylvania: Check PA PDMP before each benzodiazepine or opioid prescription (not just the first)
• Texas: Mandatory check for opioids, benzos, barbiturates, and carisoprodol before prescribing
• Florida: Check E-FORCSE before any controlled substance prescription and every 90 days for continued therapy
• Illinois: Check state PMP for all Schedule II prescriptions and document the query

Most modern EHRs integrate PDMP access, but you’re legally responsible for compliance even if it adds 2-3 minutes per patient.

3. E-Prescribing RequirementsThe majority of states now mandate electronic prescribing for controlled substances:

• California and New York require e-prescribing for all medications, controlled or not
• Florida, Pennsylvania, and Illinois require it for controlled substances specifically
• Texas strongly encourages it and most pharmacies expect it

You’ll need a DEA-compliant EPCS system with two-factor authentication. Paper prescriptions for controlled substances are essentially obsolete in telehealth practice.

PMHNPs: Full Clinical Capability, Variable Regulatory Authority

Psychiatric Mental Health Nurse Practitioners can diagnose and treat anxiety disorders in every state. The regulatory complexity lies in practice authority (can you work independently?) and prescriptive authority limits (what can you prescribe, particularly controlled substances?).

Independent vs. Collaborative Practice

States fall into three categories:

Full Practice Authority (No Physician Oversight Required):

• Illinois: After 4,000 clinical hours and additional training, PMHNPs can practice and prescribe independently (with a limited physician consultation requirement for Schedule II opioids in first 5 years of FPA)
• New York: After 3,600 hours of practice under physician collaboration, NPs gain full independence—no written agreement needed
• California: Transitioning—experienced NPs gained limited independence in 2023; full independent practice across all settings available by January 2026 under AB 890

Restricted Practice (Physician Collaboration Required):

• Texas: Must work under a Prescriptive Authority Agreement (PAA) with a physician throughout career
• Florida: Requires supervisory protocol with a physician (psychiatric NPs are excluded from the state’s primary care NP independence pathway)
• Pennsylvania: Collaborative agreement with physician required (bills for NP independence introduced but not enacted as of 2025)

Controlled Substance Prescribing: State-Specific Limits

Schedule IV (Benzodiazepines)—The Main Anxiety Class:Nearly all states permit PMHNPs to prescribe Schedule IV anxiolytics, but with variations:

• Pennsylvania: Can prescribe up to 90-day supply of Schedule IV (including benzos) under collaborative agreement
• Florida: No quantity limits for psychiatric NPs treating mental health conditions; general NPs face restrictions
• Texas: Can prescribe Schedule III-IV under PAA (most benzodiazepines are Schedule IV)
• New York, California, Illinois: Full prescriptive authority for experienced/independent NPs

Schedule II (Stimulants for Comorbid ADHD)—Major Restrictions:This is where NP practice gets complicated:

• Texas: APRNs cannot prescribe Schedule II in outpatient settings except in hospitals or for hospice patients. Period. A Texas PMHNP cannot independently start Adderall for an ADHD/anxiety patient via telehealth.
• Florida: NPs limited to 7-day supply of Schedule II unless they’re a certified psychiatric nurse treating mental illness (then no limit)
• Pennsylvania: Can prescribe Schedule II for up to 30-day supply under collaborative agreement (physician must be notified within 24 hours)
• Illinois: Independent NPs can prescribe Schedule II non-narcotics (like stimulants) without physician consult; Schedule II opioids require consultation relationship for first 5 years of FPA
• California & New York: Experienced/independent NPs can prescribe Schedule II with DEA registration and state authority

What This Means Practically

If you’re a PMHNP treating anxiety via telehealth:

• In New York or Illinois (with FPA): You can independently manage the full spectrum of anxiety treatment, including benzodiazepines and comorbid ADHD stimulants
• In Texas or Pennsylvania: You’ll need a collaborating physician and cannot prescribe certain Schedule II medications (TX) or need oversight for all controlled prescribing
• In Florida: You can prescribe psychiatric medications including controlled substances, but work under a physician protocol
• In California: Transitioning to full independence by 2026; currently still require standardized procedures with physician approval

Most telehealth platforms (including Klarity Health) handle these arrangements—ensuring you have appropriate physician collaborators in restrictive states or enabling full independence where allowed.

State-by-State Telehealth Prescribing Rules

Beyond scope of practice, each state has specific telehealth regulations that affect how you can prescribe anxiety medications:

California

• No in-person exam required if telehealth evaluation meets standard of care
• E-prescribing mandatory for all prescriptions (since 2022)
• Must check CURES PDMP for Schedule II-IV drugs at least every 4 months
• Not in IMLC—requires separate CA license for out-of-state psychiatrists
• No state restrictions on tele-prescribing controlled substances beyond federal law

Texas

• Requires real-time audio-visual examination to establish patient relationship
• Cannot use telehealth for chronic pain management with controlled substances (doesn’t affect anxiety treatment)
• Mandatory TX PMP check for opioids, benzos, barbiturates, carisoprodol
• IMLC member (easier multi-state licensing for physicians)
• NPs face Schedule II prescribing prohibition outside hospital/hospice settings

Florida

• Explicit psychiatric disorder exception: Can prescribe Schedule II controlled substances via telehealth only for psychiatric treatment, inpatient, hospice, or nursing home care
• Must obtain patient consent for telehealth treatment (documented)
• Out-of-state telehealth registration available—licensed providers in other states can register to treat FL patients without full FL license
• Must check E-FORCSE PDMP before any controlled substance prescription and every 90 days thereafter
• E-prescribing required for all controlled substances
• IMLC member

New York

• No state-mandated in-person exam for telehealth prescribing
• Mandatory I-STOP PDMP check before every Schedule II-IV prescription
• E-prescribing required for all medications (since 2016)
• Experienced NPs (3,600+ hours) have full practice authority
• Not in IMLC—separate license required for out-of-state psychiatrists
• Audio-only telehealth approved for some mental health services (though video preferred for initial evaluations)

Pennsylvania

• No comprehensive telehealth statute, but boards permit telemedicine if standard of care met
• Must check PA PDMP before each benzodiazepine or opioid prescription (not just initially)
• E-prescribing mandatory for controlled substances (since 2019)
• NPs can prescribe Schedule IV benzos up to 90-day supply under collaborative agreement
• IMLC member for physicians

Illinois

• Telehealth-friendly—no in-person exam requirement
• Audio-only telehealth permitted for mental health services when necessary
• Must register with and check Illinois PMP for Schedule II prescriptions
• NPs with Full Practice Authority can prescribe independently after 4,000 hours
• Requires separate state controlled substance license in addition to DEA registration
• IMLC member for physicians; joined Nurse Licensure Compact (RN level) in 2022

The Economic Reality: Why Platforms Like Klarity Make Sense

Here’s what most providers don’t calculate when considering DIY telehealth marketing:

True patient acquisition costs for psychiatric services run $200-500+ per patient when you factor in:

• SEO investment ($1,000-3,000/month for 6-12 months before meaningful results)
• Google Ads at $15-40+ per click for mental health keywords (most clicks don’t convert)
• Psychology Today directory fees ($30-50/month) where you compete with hundreds of providers
• Staff time qualifying leads, managing no-shows from cold traffic
• Failed campaign optimization and testing

Klarity’s model eliminates that risk entirely: You pay a standard listing fee per qualified new patient who books with you. No upfront marketing spend. No monthly subscriptions. No gambling on whether your SEO will ever generate leads.

You get:

• Pre-qualified patients matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Automated compliance systems (e-prescribing, PDMP integration where available)
• Multi-state licensing support
• Both insurance and cash-pay patient flow

The math is simple: would you rather spend $3,000-5,000/month on marketing with uncertain ROI, or pay only when a qualified anxiety patient actually shows up for their appointment?

For psychiatrists and PMHNPs starting a telehealth practice or scaling existing services, a platform that handles patient acquisition removes the biggest barrier to growth. You control your schedule, set your clinical approach, and only pay for results.

What to Expect in 2025-2026: Regulatory Outlook

Federal DEA Rules:The current telehealth prescribing flexibilities expire December 31, 2025. The DEA is developing new permanent rules. Expect one of three scenarios:

1. Full extension of current flexibilities (allowing telehealth-only controlled prescribing)
2. Hybrid model—initial prescription via telehealth with eventual in-person requirement (e.g., within 30 days for benzodiazepines)
3. Special telehealth DEA registration—providers could register specifically for telemedicine controlled prescribing

Most industry observers expect scenario 2 or 3, with psychiatry potentially getting more favorable treatment than other specialties given the mental health crisis.

State Trends:The movement toward NP full practice authority continues. Pennsylvania and other holdout states will likely face pressure to grant PMHNP independence as psychiatrist shortages worsen. California’s full implementation of AB 890 in 2026 will create the largest independent NP workforce in the country.

Compliance Technology:Expect increased integration of PDMP systems with EHRs, AI-assisted prescription monitoring alerts, and more sophisticated telehealth platform compliance tools. The administrative burden should decrease as technology catches up with regulations.

Key Takeaways for Providers

If you’re a psychiatrist:

• Your scope is unrestricted—focus on licensing and prescribing compliance
• Multi-state practice requires either IMLC membership or individual state licenses
• PDMP checks and e-prescribing are non-negotiable in most states
• Telehealth platforms can handle much of the administrative burden while you focus on clinical care

If you’re a PMHNP:

• Know your state’s practice authority—independent states (NY, IL, CA by 2026) offer more autonomy
• Understand controlled substance limits in restrictive states (especially Texas Schedule II prohibition)
• Even in collaborative-practice states, you can provide full anxiety treatment with appropriate physician agreements
• Platform-based practice often provides built-in collaborative relationships in states that require them

For both:

• Current federal rules allow remote controlled prescribing through at least end of 2025
• Stay informed about DEA rule changes—join professional associations that track telehealth policy
• Document thoroughly—telehealth visits must meet the same standard of care as in-person
• Consider platforms like Klarity that guarantee patient flow without marketing risk

The regulatory landscape for telehealth psychiatry is complex, but it’s also more permissive than ever. With proper licensing, compliance systems, and the right practice model, you can build a thriving anxiety-focused telehealth practice that serves patients across multiple states.

The question isn’t whether telehealth prescribing is legal—it is. The question is whether you’re positioned to navigate the state-by-state variations efficiently while focusing on what you do best: treating patients.

Frequently Asked Questions

Can I prescribe benzodiazepines to a new patient via telehealth in 2025?Yes, under current federal DEA rules (extended through December 31, 2025). You can conduct a video evaluation and prescribe Schedule IV benzodiazepines without any in-person visit, provided you meet state licensing requirements and standard of care. This flexibility may change in 2026 when new DEA rules are finalized.

Do I need a separate license in every state where I treat patients via telehealth?Yes. Even though treatment is delivered remotely, you must be licensed in the state where the patient is physically located during the visit. The Interstate Medical Licensure Compact (IMLC) can expedite this process for physicians in member states (TX, FL, IL, PA—but not CA or NY).

What’s the difference between Schedule II and Schedule IV anxiety medications?Schedule IV includes most benzodiazepines (Xanax, Klonopin, Ativan, Valium)—these are typically used for anxiety and panic disorders. Schedule II includes stimulants (Adderall, Ritalin) sometimes prescribed for comorbid ADHD with anxiety. Schedule II has stricter prescribing rules, especially for NPs in states like Texas (where NPs cannot prescribe Schedule II outside hospitals).

Can PMHNPs prescribe anxiety medications independently?It depends on the state. In New York (after 3,600 hours), Illinois (with Full Practice Authority), and California (by 2026), experienced PMHNPs can practice and prescribe completely independently. In Texas, Florida, and Pennsylvania, NPs must work under physician collaboration or supervision agreements but can still provide full anxiety treatment within those arrangements.

Do I need to check the prescription monitoring database for every controlled substance prescription?In most states, yes. New York requires a PDMP check before every Schedule II-IV prescription. Pennsylvania requires it before each benzodiazepine prescription. California requires it initially and every 4 months. Texas and Florida have similar mandatory check requirements. Only a few states have more relaxed rules, and even there, checking is best practice for controlled substances.

What happens if the DEA changes telehealth prescribing rules in 2026?If new rules require an in-person exam for controlled substances, providers would need to either: (1) see patients in person before prescribing benzodiazepines, (2) use a hybrid model with affiliated clinics for initial visits, or (3) obtain a special telehealth DEA registration if created. SSRIs, SNRIs, and other non-controlled anxiety medications would remain fully prescribable via telehealth.

Can I treat patients via audio-only (phone) or must I use video?Most states strongly prefer or require video for initial evaluations and controlled substance prescribing. Illinois explicitly permits audio-only for mental health services when necessary. For follow-up visits with established patients, audio-only is generally acceptable. Always use video when possible for better clinical assessment and regulatory compliance.

How do platforms like Klarity Health handle multi-state compliance?Reputable telehealth platforms provide: (1) credentialing support for multi-state licensing, (2) built-in e-prescribing with PDMP integration where available, (3) physician collaboration arrangements in states requiring NP oversight, (4) compliance monitoring for changing regulations, and (5) documentation systems that meet state-specific requirements. This removes most of the administrative burden from individual providers.

Citations & Sources

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, Press Release, November 15, 2024. Available at: https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. 21 U.S.C. § 829(e) – Ryan Haight Online Pharmacy Consumer Protection Act of 2008 – Federal controlled substance prescribing requirements. Available at: https://www.law.cornell.edu/uscode/text/21/829

3. Center for Connected Health Policy – State Telehealth Policies: Online Prescribing – Comprehensive summary of state telehealth and prescribing laws, updated January 9, 2026. Available at: https://www.cchpca.org/topic/online-prescribing/

4. Florida Statutes § 456.47 – Telehealth Services – Florida’s telehealth law including controlled substance prescribing exceptions, 2025 edition. Available at: http://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/0456.html

5. Texas Board of Nursing – APRN Prescriptive Authority FAQ – Guidance on NP Schedule II prescribing limitations in Texas, updated December 9, 2025. Available at: https://www.bon.texas.gov/faqpracticeaprn.asp.html

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94